MedTrace Logo

The Efficiency of MSC in Refractory Crohn's Disease

NCT02532738 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2015-08-26

No results posted yet for this study

Summary

The investigators' preliminary study indicates that MSC is effective therapy in treating IBD. But the standard treatment is still lacking and the effect is not stable in IBD patients. This study is to explore the efficacy and standard strategy when using MSC in refractory IBD.

Conditions

Interventions

DRUG

Routine Treatment of CD

The Drug including 6MP, AZA, infliximab and thalidomide

BIOLOGICAL

MSC treatment 01

Injection of 3×10E6/kg of MSC

BIOLOGICAL

MSC treatment 02

Injection of 6×10E6/kg of MSC

OTHER

NS

Injection of NS

Sponsors & Collaborators

  • Third Affiliated Hospital, Sun Yat-Sen University

    collaborator OTHER

  • Nanfang Hospital, Southern Medical University

    collaborator OTHER

  • Sixth Affiliated Hospital, Sun Yat-sen University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2018-11-30
Completion
2018-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02532738 on ClinicalTrials.gov